Wierenga Wendall
SEC-identified person · CIK 1235945 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Cytokinetics INC CYTK | Director | filed 2011 - 2025 |
| Crinetics Pharmaceuticals, Inc. CRNX | Director | filed 2018 - 2025 |
| Concert Pharmaceuticals, INC. N/A | Director | filed 2014 - 2018 |
| Seelos Therapeutics, INC. SEEL | Director | filed 2014 - 2018 |
| Tranzyme INC TZYM | Director | filed 2013 - 2017 |
| Xenoport INC XNPT | Director | filed 2006 - 2016 |
| Anacor Pharmaceuticals, Inc. ANAC | Director | filed 2014 - 2016 |
| Santarus INC SNTS | EVP, R&D | filed 2011 - 2014 |
| Onyx Pharmaceuticals INC ONXX | Director | filed 2006 - 2013 |
| Neurocrine Biosciences INC NBIX | EVP, Research & Development | filed 2006 - 2006 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.